Trial Profile
A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naive Adults
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms Gemini 2
- Sponsors ViiV Healthcare
- 26 Oct 2022 Results0f 48 week subgroup analyses of the GEMINI-1/-2 and STAT trials, presented at the 16th International Congress on Drug Therapy and HIV Infection
- 15 Jul 2022 Status changed from active, no longer recruiting to completed.
- 12 May 2022 Status changed from completed to active, no longer recruiting.